ALLMedicine™ Acute Myeloblastic Leukemia Center
Research & Reviews 149 results
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.
Dec 29th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.
May 20th, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083
Blood Cancer Journal; Pulte D, Jansen L et. al.
May 14th, 2020 - Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (...
https://clinicaltrials.gov/ct2/show/NCT01296178
Apr 8th, 2020 - Primary objectives Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival...
https://doi.org/10.1080/10428194.2020.1737685
Leukemia & Lymphoma; Guolo F, Minetto P et. al.
Mar 18th, 2020 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a poor prognosis myeloid malignancy characterized by an atypical phenotype (CD123+, CD56+, and CD4+). We reported that BPDCN-like phenotype (CD123+ and either CD56+ or CD4+ or both) confers p...
Clinicaltrials.gov 149 results
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.
Dec 29th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.
May 20th, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083
Blood Cancer Journal; Pulte D, Jansen L et. al.
May 14th, 2020 - Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (...
https://clinicaltrials.gov/ct2/show/NCT01296178
Apr 8th, 2020 - Primary objectives Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival...
https://doi.org/10.1080/10428194.2020.1737685
Leukemia & Lymphoma; Guolo F, Minetto P et. al.
Mar 18th, 2020 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a poor prognosis myeloid malignancy characterized by an atypical phenotype (CD123+, CD56+, and CD4+). We reported that BPDCN-like phenotype (CD123+ and either CD56+ or CD4+ or both) confers p...
